Leading From The Lab: MIT’s Robert Langer On The Converging Science Of Drugs, Devices And Delivery

"If one has the essential ingredients of a good idea, a patent, data and some talented people, you can often start a company."

Ten years after our first encounter with MIT’s Robert Langer, In Vivo sits down with the polymath professor – arguably the most inventive and prolific life scientist of his generation – to identify key challenges in medicine. 

Langer_Bob_1200.jpg
Bob Langer, MIT • Source: Bachrach

More from Business Strategy

More from In Vivo

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

 
• By 

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.